Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Journal of Hospital Medicine
|
July 28, 2018
Reply to Azithromycin: Short Course with Long Duration
Stephanie Royer, Hallie C Prescott
Critical Care Medicine
|
December 19, 2017
Next Steps for Confirming Bronchoalveolar Lavage Amlyase as an Useful Biomarker for Ventilator-Associated Pneumonia
Stephanie Royer, Hallie C Prescott
Journal of Hospital Medicine
|
January 26, 2018
Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis
Stephanie Royer, Kimberley M DeMerle, Robert P Dickson, et al.
Clinical Colorectal Cancer
|
October 1, 2013
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer
Zev A Wainberg, Wells A Messersmith, Parvin F Peddi, et al.
Gynecologic Oncology
|
October 10, 2021
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
Joyce Liu, Howard Burris, Judy S Wang, et al.
Cancer Investigation
|
October 16, 2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer
Caio M Rocha Lima, Soley Bayraktar, Aurea M Flores, et al.
Cancer
|
August 16, 2016
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Jean-Pascal Machiels, Lori Wirth, et al.
British Journal of Clinical Pharmacology
|
April 12, 2019
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
Shuguang Ma, Julia Suchomel, Evelyn Yanez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Yoonha Choi, Neekesh V Dharia, Tomi Jun, et al.
Gynecologic Oncology
|
June 15, 2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
Kathleen N Moore, Michael J Birrer, Jim Marsters, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Journal of Hospital Medicine
|
July 28, 2018
Reply to Azithromycin: Short Course with Long Duration
Stephanie Royer, Hallie C Prescott
Critical Care Medicine
|
December 19, 2017
Next Steps for Confirming Bronchoalveolar Lavage Amlyase as an Useful Biomarker for Ventilator-Associated Pneumonia
Stephanie Royer, Hallie C Prescott
Journal of Hospital Medicine
|
January 26, 2018
Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis
Stephanie Royer, Kimberley M DeMerle, Robert P Dickson, et al.
Clinical Colorectal Cancer
|
October 1, 2013
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer
Zev A Wainberg, Wells A Messersmith, Parvin F Peddi, et al.
Gynecologic Oncology
|
October 10, 2021
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
Joyce Liu, Howard Burris, Judy S Wang, et al.
Cancer Investigation
|
October 16, 2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer
Caio M Rocha Lima, Soley Bayraktar, Aurea M Flores, et al.
Cancer
|
August 16, 2016
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Jean-Pascal Machiels, Lori Wirth, et al.
British Journal of Clinical Pharmacology
|
April 12, 2019
Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
Shuguang Ma, Julia Suchomel, Evelyn Yanez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Yoonha Choi, Neekesh V Dharia, Tomi Jun, et al.
Gynecologic Oncology
|
June 15, 2020
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
Kathleen N Moore, Michael J Birrer, Jim Marsters, et al.
Page
of 2